Literature DB >> 21304504

Radiotherapy: has the role of WBRT in primary CNS lymphoma been settled?

Lisa M DeAngelis1.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21304504     DOI： 10.1038/nrclinonc.2011.18

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.

Authors:  Eckhard Thiel; Agnieszka Korfel; Peter Martus; Lothar Kanz; Frank Griesinger; Michael Rauch; Alexander Röth; Bernd Hertenstein; Theda von Toll; Thomas Hundsberger; Hans-Günther Mergenthaler; Malte Leithäuser; Tobias Birnbaum; Lars Fischer; Kristoph Jahnke; Ulrich Herrlinger; Ludwig Plasswilm; Thomas Nägele; Torsten Pietsch; Michael Bamberg; Michael Weller
Journal:  Lancet Oncol       Date:  2010-10-20       Impact factor: 41.316

2.  Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

Authors:  Lisa M DeAngelis; Wendy Seiferheld; S Clifford Schold; Barbara Fisher; Christopher J Schultz
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

Review 3.  Primary central nervous system lymphoma.

Authors:  Elizabeth R Gerstner; Tracy T Batchelor
Journal:  Arch Neurol       Date:  2010-03

4.  Delayed neurotoxicity in primary central nervous system lymphoma.

Authors:  Antonio M P Omuro; Leah S Ben-Porat; Katherine S Panageas; Amy K Kim; Denise D Correa; Joachim Yahalom; Lisa M Deangelis; Lauren E Abrey
Journal:  Arch Neurol       Date:  2005-10

5.  Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?

Authors:  Antonio Omuro; Luc Taillandier; Olivier Chinot; Monica Sierra Del Rio; Charlotte Carnin; Marylin Barrie; Carole Soussain; Marie-Laure Tanguy; Sylvain Choquet; Veronique Leblond; Khe Hoang-Xuan
Journal:  J Neurooncol       Date:  2010-12-19       Impact factor: 4.130

6.  Treatment for primary CNS lymphoma: the next step.

Authors:  L E Abrey; J Yahalom; L M DeAngelis
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

7.  Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.

Authors:  E M Bessell; A López-Guillermo; S Villá; E Verger; B Nomdedeu; J Petit; P Byrne; E Montserrat; Francesc Graus
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

8.  Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.

Authors:  Gaurav D Shah; Joachim Yahalom; Denise D Correa; Rose K Lai; Jeffrey J Raizer; David Schiff; Renato LaRocca; Barbara Grant; Lisa M DeAngelis; Lauren E Abrey
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

9.  Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy.

Authors:  Denise D Correa; Mary Rocco-Donovan; Lisa M DeAngelis; Rima Dolgoff-Kaspar; Fabio Iwamoto; Joachim Yahalom; Lauren E Abrey
Journal:  J Neurooncol       Date:  2008-11-01       Impact factor: 4.130
  9 in total
  3 in total

1.  Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.

Authors:  Christian Grommes; James L Rubenstein; Lisa M DeAngelis; Andres J M Ferreri; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

Review 2.  Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents.

Authors:  Andrés José María Ferreri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.

Authors:  Mina Lobbous; L Burt Nabors; Andrew B DeAtkine; Moaaz Abdelrashid; Zach Tucker; Amitkumar Mehta; James M Markert; Jinsuh Kim; John B Fiveash; Robert A Oster
Journal:  J Neurooncol       Date:  2022-04-20       Impact factor: 4.130
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.